Alliancebernstein L.P. Raises Holdings in Humana Inc. $HUM

Alliancebernstein L.P. lifted its stake in Humana Inc. (NYSE:HUM - Free Report) by 3.0% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 155,642 shares of the insurance provider's stock after buying an additional 4,547 shares during the quarter. Alliancebernstein L.P. owned approximately 0.13% of Humana worth $41,183,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of HUM. Revolve Wealth Partners LLC purchased a new stake in shares of Humana in the fourth quarter worth about $202,000. Ethic Inc. boosted its stake in shares of Humana by 7.7% in the fourth quarter. Ethic Inc. now owns 8,641 shares of the insurance provider's stock worth $2,192,000 after buying an additional 619 shares during the last quarter. Gotham Asset Management LLC boosted its stake in shares of Humana by 38.9% in the fourth quarter. Gotham Asset Management LLC now owns 32,593 shares of the insurance provider's stock worth $8,269,000 after buying an additional 9,132 shares during the last quarter. Integral Health Asset Management LLC purchased a new stake in shares of Humana in the fourth quarter worth about $10,148,000. Finally, Meridiem Capital Partners LP purchased a new stake in shares of Humana in the fourth quarter worth about $9,264,000. Hedge funds and other institutional investors own 92.38% of the company's stock.

Humana Trading Up 0.1%

Shares of HUM traded up $0.33 during midday trading on Wednesday, hitting $273.35. 4,315,620 shares of the stock were exchanged, compared to its average volume of 1,490,559. Humana Inc. has a 52-week low of $206.87 and a 52-week high of $333.79. The stock has a fifty day simple moving average of $263.78 and a 200 day simple moving average of $256.90. The firm has a market cap of $32.88 billion, a P/E ratio of 20.98, a P/E/G ratio of 1.60 and a beta of 0.44. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing the consensus estimate of $6.32 by ($0.05). Humana had a return on equity of 13.67% and a net margin of 1.28%.The firm had revenue of $32.39 billion for the quarter, compared to analysts' expectations of $31.85 billion. During the same quarter in the prior year, the business earned $6.96 earnings per share. The company's quarterly revenue was up 9.6% on a year-over-year basis. Humana has set its FY 2025 guidance at 17.000- EPS. On average, research analysts anticipate that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be issued a dividend of $0.885 per share. The ex-dividend date is Friday, September 26th. This represents a $3.54 annualized dividend and a yield of 1.3%. Humana's dividend payout ratio is 27.17%.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on HUM shares. Wall Street Zen cut Humana from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. Bank of America upped their price target on Humana from $285.00 to $312.00 and gave the stock a "neutral" rating in a report on Tuesday, September 2nd. Robert W. Baird reduced their price target on Humana from $300.00 to $297.00 and set a "neutral" rating for the company in a report on Friday, July 25th. Barclays increased their target price on Humana from $275.00 to $315.00 and gave the company an "equal weight" rating in a report on Friday, September 5th. Finally, Truist Financial reduced their target price on Humana from $280.00 to $260.00 and set a "hold" rating for the company in a report on Wednesday, July 16th. Seven investment analysts have rated the stock with a Buy rating and sixteen have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Humana currently has a consensus rating of "Hold" and an average price target of $289.24.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.